MedTrace Logo

The Health Burden of Primary Biliary Cirrhosis (PBC) in Switzerland

NCT02846896 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 501

Last updated 2025-08-19

No results posted yet for this study

Summary

PBC is a rare, autoimmune, cholestatic liver disease with genetic and environmental pathogenetic factors. Data about epidemiology of PBC in Switzerland are completely lacking. Epidemiology can be a powerful tool in yielding important clues as to burden and etiology of diseases. In addition, the investigators study will be the first one carried out in the country on PBC, and therefore will raise disease awareness and create a network.

Conditions

  • Primary Biliary Cirrhosis

Sponsors & Collaborators

  • Vifor Pharma

    collaborator INDUSTRY

  • Intercept Pharmaceuticals

    collaborator INDUSTRY

  • Fondazione Epatocentro Ticino

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2016-09-30
Completion
2017-03-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02846896 on ClinicalTrials.gov